Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
0.0985
-0.0065 (-6.19%)
At close: Apr 28, 2025, 4:00 PM
0.1000
+0.0015 (1.52%)
After-hours: Apr 28, 2025, 4:56 PM EDT
Lyra Therapeutics Stock Forecast
LYRA's stock price has decreased by -97.91% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Lyra Therapeutics stock have an average target of 1.25, with a low estimate of 0.50 and a high estimate of 2.00. The average target predicts an increase of 1,169.04% from the current stock price of 0.10.
Analyst Consensus: Hold
* Price targets were last updated on Mar 14, 2025.
Analyst Ratings
The average analyst rating for Lyra Therapeutics stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $2 | Hold | Reiterates | $2 | +1,930.46% | Mar 14, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Aug 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $2 | Hold | Reiterates | $2 | +1,930.46% | Aug 15, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $2 | Strong Buy → Hold | Downgrades | $2 | +1,930.46% | May 7, 2024 |
Financial Forecast
Revenue This Year
1.17M
from 1.53M
Decreased by -23.66%
Revenue Next Year
3.95M
from 1.17M
Increased by 237.15%
EPS This Year
-0.73
from -1.43
EPS Next Year
-0.86
from -0.73
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.6M | 7.7M | 27.3M | ||
| Avg | 1.2M | 3.9M | 26.5M | ||
| Low | 392,000 | 392,000 | 25.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.6% | 558.3% | 591.6% | ||
| Avg | -23.7% | 237.1% | 571.9% | ||
| Low | -74.4% | -66.5% | 545.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.38 | -0.86 | -0.71 |
| Avg | -0.73 | -0.86 | -0.69 |
| Low | -1.01 | -0.84 | -0.67 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.